Reva Schneider

495 total citations
17 papers, 353 citations indexed

About

Reva Schneider is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Reva Schneider has authored 17 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Reva Schneider's work include Cancer Immunotherapy and Biomarkers (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and interferon and immune responses (2 papers). Reva Schneider is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and interferon and immune responses (2 papers). Reva Schneider collaborates with scholars based in United States, United Kingdom and South Korea. Reva Schneider's co-authors include Elizabeth Odstrcil, Joseph A. Kuhn, Juan Gabriel Martı́nez, John R. Asplin, Carol A. Santa Ana, John S. Fordtran, Jack L. Porter, Cynthia R. Osborne, John Pippen and Sandip Pravin Patel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Clinical Nutrition.

In The Last Decade

Reva Schneider

15 papers receiving 348 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reva Schneider United States 7 135 119 117 86 57 17 353
Tına Mistry United Kingdom 6 58 0.4× 106 0.9× 82 0.7× 54 0.6× 80 1.4× 9 392
Sefa Tüzün Türkiye 10 58 0.4× 95 0.8× 68 0.6× 45 0.5× 95 1.7× 30 324
Jiaze Hong China 11 83 0.6× 126 1.1× 67 0.6× 20 0.2× 42 0.7× 26 338
Katharina M. Scheurlen United States 12 154 1.1× 67 0.6× 85 0.7× 50 0.6× 126 2.2× 31 378
Kazuo To Japan 9 112 0.8× 87 0.7× 94 0.8× 16 0.2× 63 1.1× 16 329
J‐Y Scoazec France 6 95 0.7× 42 0.4× 86 0.7× 25 0.3× 78 1.4× 8 348
Amelia Sybenga United States 10 89 0.7× 52 0.4× 25 0.2× 32 0.4× 47 0.8× 16 259
J. Wolf United States 5 62 0.5× 106 0.9× 38 0.3× 70 0.8× 102 1.8× 7 361
Yoshinori Ozeki Japan 9 91 0.7× 111 0.9× 45 0.4× 25 0.3× 45 0.8× 23 303
N. Ansorge Germany 9 161 1.2× 97 0.8× 23 0.2× 29 0.3× 96 1.7× 15 358

Countries citing papers authored by Reva Schneider

Since Specialization
Citations

This map shows the geographic impact of Reva Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reva Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reva Schneider more than expected).

Fields of papers citing papers by Reva Schneider

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reva Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reva Schneider. The network helps show where Reva Schneider may publish in the future.

Co-authorship network of co-authors of Reva Schneider

This figure shows the co-authorship network connecting the top 25 collaborators of Reva Schneider. A scholar is included among the top collaborators of Reva Schneider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reva Schneider. Reva Schneider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Luke, Jason J., Randy F. Sweis, J. Randolph Hecht, et al.. (2025). Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(7). 1233–1242. 10 indexed citations
2.
3.
4.
Simpkins, Fiona, Amit Mahipal, Patricia LoRusso, et al.. (2024). Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors. Cancer Research. 84(7_Supplement). CT196–CT196. 2 indexed citations
5.
Tinker, Anna V., James Strauss, Reva Schneider, et al.. (2023). A phase II study of tinostamustine in patients (pts) with advanced solid tumours.. Journal of Clinical Oncology. 41(16_suppl). 3021–3021.
6.
Naing, Aung, Meredith Pelster, Alexander I. Spira, et al.. (2022). 747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors. Regular and Young Investigator Award Abstracts. A780–A780. 4 indexed citations
7.
Williamson, Stephen K., F. Stephen Hodi, Melissa L. Johnson, et al.. (2021). Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.. Journal of Clinical Oncology. 39(15_suppl). 2510–2510. 3 indexed citations
8.
Glisson, Bonnie S., Rom S. Leidner, Robert L. Ferris, et al.. (2020). Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(20). 5358–5367. 63 indexed citations
9.
Callahan, Margaret K., Kunle Odunsi, Mario Sznol, et al.. (2019). Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors. Cancer Immunology Research. 7(2_Supplement). A006–A006. 1 indexed citations
10.
Glisson, Bonnie S., Rom S. Leidner, Robert L. Ferris, et al.. (2018). Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. Annals of Oncology. 29. viii410–viii410. 20 indexed citations
11.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Molecular Therapy. 23(6). 1103–1109. 48 indexed citations
12.
Barve, Minal, Reva Schneider, Robert Mennel, et al.. (2015). Pilot trial of vigil immunotherapy in Ewing’s sarcoma.. Journal of Clinical Oncology. 33(15_suppl). 10522–10522. 4 indexed citations
13.
Schneider, Reva, et al.. (2013). Results of an Educational Program to Promote the Use of Pooled Instead of Single-Donor Platelet Transfusions. Baylor University Medical Center Proceedings. 26(1). 3–5. 1 indexed citations
14.
Miller, Alan M., Reva Schneider, Estil Vance, et al.. (2013). Differential Gene Expression Analysis Predicts For Response To Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD). Blood. 122(21). 4587–4587. 1 indexed citations
15.
Schneider, Reva, et al.. (2011). Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer Targets and Therapy. 3. 113–113. 31 indexed citations
16.
Odstrcil, Elizabeth, Juan Gabriel Martı́nez, Carol A. Santa Ana, et al.. (2010). The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. American Journal of Clinical Nutrition. 92(4). 704–713. 158 indexed citations
17.
Hackenberg, K., Reva Schneider, & D. Reinwein. (1972). THYROIDAL SUPPRESSIBILITY AND THYROGLOBULIN ANTIBODIES DURING TREATMENT OF THYROTOXICOSIS WITH ANTITHYROID DRUGS. European Journal of Endocrinology. 68(3_Suppl). S9–S9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tına Mistry Breakdown of academic impact, for papers by Sefa Tüzün Breakdown of academic impact, for papers by Jiaze Hong Breakdown of academic impact, for papers by Katharina M. Scheurlen Breakdown of academic impact, for papers by Kazuo To Breakdown of academic impact, for papers by J‐Y Scoazec Breakdown of academic impact, for papers by Amelia Sybenga Breakdown of academic impact, for papers by J. Wolf Breakdown of academic impact, for papers by Yoshinori Ozeki Breakdown of academic impact, for papers by N. Ansorge
Rankless by CCL
2026